Continuous peripheral nerve blocks for analgesia of ventilated critically ill patients with multiple trauma: a prospective randomized study
Authors' conclusion
CRA does not decrease significantly sufentanil and midazolam consumption within the first 5 days after ICU admission in multiple trauma-ventilated patients.
Study context
- Population
- Ventilated critically ill patients with multiple trauma76 analysed
- Participants
- 40 vs 36
- Comparison
- IV analgesia plus continuous regional analgesia vs IV analgesia alone
- Controln = 40reference
- Continuous regional analgesia (CRA)n = 36
- Primary endpoint
- Cumulative consumption of sufentanil
- Follow-up
- 2 days of admission
Methodological detailsprospective
- Prospective
Primary result
As reported in the abstract
Cumulative sufentanil consumption · 48h
Sufentanil consumption at 48h, median [IQR], groups as ordered in the abstract (group not named in the sentence)
725 [465-960] μg/48h versus 670 [510-940] μg/48h
Secondary outcomes
- Daily sufentanil consumption · day 1 — Daily consumption did not differ except on day 1; day 1 sufentanil, median [IQR] (group not named in the sentence)
- 360 [270-480] μg vs. 480 [352-535] μg · P = 0.03
Midazolam consumption
- Did not differ between groups
Other secondary endpoints (mechanical ventilation duration, intensive care unit (ICU) stay)
- No difference between groups
Safety
Safety of CRA management
- Peripheral nerve blocks in heavily sedated, ventilated trauma patients in ICU seem safe
Original publication
Continuous peripheral nerve blocks for analgesia of ventilated critically ill patients with multiple trauma: a prospective randomized study. Anaesth Crit Care Pain Med. Published 8 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →